Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-10-07

AUTHORS

Hiroya Narumi, Hiroyuki Takano, Satoshi Shindo, Miwa Fujita, Hiroshi Mizuma, Yoichi Kuwabara, Issei Komuro,

ABSTRACT

The Valsartan Amlodipine Randomized Trial, a multicenter, prospective, randomized, open-labeled, blinded-end point trial, was designed to compare the beneficial effects of the angiotensin II receptor blocker valsartan and the calcium channel blocker amlodipine on cardiovascular events in Japanese essential hypertensive patients. The primary end point was a composite of all-cause death, sudden death, cerebrovascular death, cardiac events, vascular events and renal events. The secondary endpoints were effects on left ventricular hypertrophy, cardiac sympathetic nerve activity and renal function. A total of 1021 patients were enrolled in the present trial. The mean follow-up period was 3.4 years. There were no significant differences in blood pressure (BP) levels between the valsartan group and the amlodipine group throughout the trial. There was no significant difference in the primary endpoint between the two groups (hazard ratio: 1.0, P=0.843). No difference in any event category of the primary endpoint was noted for either group. However, we observed a significant reduction of left ventricular mass index, as determined by echocardiography, in the valsartan group compared with the amlodipine group. We also observed a significant decrease in cardiac sympathetic nerve activity in the valsartan group but not in the amlodipine group. Moreover, there was a significant reduction in the urinary albumin to creatinine ratio in the valsartan group but not in the amlodipine group. Therefore, although BP levels were well controlled and remained equal in the two groups, valsartan had more protective effects on the heart and kidney than amlodipine in Japanese hypertensive patients. More... »

PAGES

62-69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/hr.2010.186

DOI

http://dx.doi.org/10.1038/hr.2010.186

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046315851

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20927112


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amlodipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asian Continental Ancestry Group", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valsartan", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narumi", 
        "givenName": "Hiroya", 
        "id": "sg:person.01203207133.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takano", 
        "givenName": "Hiroyuki", 
        "id": "sg:person.0624235222.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624235222.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shindo", 
        "givenName": "Satoshi", 
        "id": "sg:person.01066760533.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066760533.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujita", 
        "givenName": "Miwa", 
        "id": "sg:person.01135073733.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135073733.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizuma", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01251322333.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251322333.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuwabara", 
        "givenName": "Yoichi", 
        "id": "sg:person.0752532133.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752532133.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komuro", 
        "givenName": "Issei", 
        "id": "sg:person.01012024207.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33"
        ], 
        "type": "Person"
      }, 
      {}
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250051259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035073261", 
          "https://doi.org/10.1007/s001250051259"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.31.21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010763509", 
          "https://doi.org/10.1291/hypres.31.21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-002-0946-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013509783", 
          "https://doi.org/10.1007/s00125-002-0946-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.31.1171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012898116", 
          "https://doi.org/10.1291/hypres.31.1171"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-10-07", 
    "datePublishedReg": "2010-10-07", 
    "description": "The Valsartan Amlodipine Randomized Trial, a multicenter, prospective, randomized, open-labeled, blinded-end point trial, was designed to compare the beneficial effects of the angiotensin II receptor blocker valsartan and the calcium channel blocker amlodipine on cardiovascular events in Japanese essential hypertensive patients. The primary end point was a composite of all-cause death, sudden death, cerebrovascular death, cardiac events, vascular events and renal events. The secondary endpoints were effects on left ventricular hypertrophy, cardiac sympathetic nerve activity and renal function. A total of 1021 patients were enrolled in the present trial. The mean follow-up period was 3.4 years. There were no significant differences in blood pressure (BP) levels between the valsartan group and the amlodipine group throughout the trial. There was no significant difference in the primary endpoint between the two groups (hazard ratio: 1.0, P=0.843). No difference in any event category of the primary endpoint was noted for either group. However, we observed a significant reduction of left ventricular mass index, as determined by echocardiography, in the valsartan group compared with the amlodipine group. We also observed a significant decrease in cardiac sympathetic nerve activity in the valsartan group but not in the amlodipine group. Moreover, there was a significant reduction in the urinary albumin to creatinine ratio in the valsartan group but not in the amlodipine group. Therefore, although BP levels were well controlled and remained equal in the two groups, valsartan had more protective effects on the heart and kidney than amlodipine in Japanese hypertensive patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/hr.2010.186", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313717", 
        "issn": [
          "0916-9636", 
          "1348-4214"
        ], 
        "name": "Hypertension Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "cardiac sympathetic nerve activity", 
      "sympathetic nerve activity", 
      "Japanese hypertensive patients", 
      "amlodipine group", 
      "valsartan group", 
      "hypertensive patients", 
      "primary endpoint", 
      "nerve activity", 
      "randomized trials", 
      "angiotensin II receptor blocker valsartan", 
      "blinded end point trial", 
      "Japanese essential hypertensive patients", 
      "calcium channel blocker amlodipine", 
      "receptor blocker valsartan", 
      "essential hypertensive patients", 
      "primary end point", 
      "ventricular mass index", 
      "effect of valsartan", 
      "blood pressure levels", 
      "left ventricular hypertrophy", 
      "channel blocker amlodipine", 
      "significant differences", 
      "significant reduction", 
      "cardiovascular events", 
      "cause death", 
      "renal events", 
      "Secondary endpoints", 
      "mean follow", 
      "cardiac events", 
      "vascular events", 
      "renal function", 
      "cardiorenal protection", 
      "cerebrovascular death", 
      "urinary albumin", 
      "ventricular hypertrophy", 
      "creatinine ratio", 
      "BP levels", 
      "mass index", 
      "point trial", 
      "sudden death", 
      "protective effect", 
      "present trial", 
      "patients", 
      "end point", 
      "beneficial effects", 
      "trials", 
      "amlodipine", 
      "valsartan", 
      "significant decrease", 
      "endpoint", 
      "death", 
      "group", 
      "pressure levels", 
      "multicenter", 
      "echocardiography", 
      "hypertrophy", 
      "follow", 
      "kidney", 
      "differences", 
      "events", 
      "effect", 
      "levels", 
      "total", 
      "activity", 
      "heart", 
      "albumin", 
      "reduction", 
      "years", 
      "event categories", 
      "index", 
      "period", 
      "decrease", 
      "protection", 
      "function", 
      "categories", 
      "ratio", 
      "point", 
      "composites", 
      "Valsartan Amlodipine Randomized Trial", 
      "Amlodipine Randomized Trial", 
      "II receptor blocker valsartan", 
      "blocker valsartan", 
      "blocker amlodipine"
    ], 
    "name": "Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial", 
    "pagination": "62-69", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046315851"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/hr.2010.186"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20927112"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/hr.2010.186", 
      "https://app.dimensions.ai/details/publication/pub.1046315851"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_504.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/hr.2010.186"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/hr.2010.186'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/hr.2010.186'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/hr.2010.186'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/hr.2010.186'


 

This table displays all metadata directly associated to this object as RDF triples.

269 TRIPLES      22 PREDICATES      129 URIs      117 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/hr.2010.186 schema:about N0c228d2d2b274781b02d3230fbf7ec71
2 N1beabae6917c4a259535dbb8e270c6e0
3 N4042ea06078c45c1bf788f2fb9228284
4 N49e4fdd0fbc749328b15e450c07fbbe3
5 N6f4ca4e1feec44288810e37892755ed1
6 N712358ee8c774639bab87ae7deb88147
7 N725bfdfb84fb41f3a9d94bacac7f93c3
8 N7e1cbd3a6ec144189670ceeaeb861bea
9 N96338d5f59724a25830d561ba5b18fdd
10 Nacc522431d54415b8a42aa88d2ed0e15
11 Nb14476c352e3442cb297a3b21c81c717
12 Nc4477d58494149e2972b83ef2d82be44
13 Nc6ce66f9ce674fc594ff6bedb6d631ea
14 Nd8aa6a9fd3794709b99ebbd6c3a47ec5
15 Nf6825a6a79584f8a9b607aed6f84b4ad
16 Nf8946af8dc4145f5a68086b4b2a1f6c0
17 anzsrc-for:11
18 anzsrc-for:1102
19 schema:author Na4b379af323b42d597be42293b02a3a2
20 schema:citation sg:pub.10.1007/s00125-002-0946-y
21 sg:pub.10.1007/s001250051259
22 sg:pub.10.1291/hypres.31.1171
23 sg:pub.10.1291/hypres.31.21
24 schema:datePublished 2010-10-07
25 schema:datePublishedReg 2010-10-07
26 schema:description The Valsartan Amlodipine Randomized Trial, a multicenter, prospective, randomized, open-labeled, blinded-end point trial, was designed to compare the beneficial effects of the angiotensin II receptor blocker valsartan and the calcium channel blocker amlodipine on cardiovascular events in Japanese essential hypertensive patients. The primary end point was a composite of all-cause death, sudden death, cerebrovascular death, cardiac events, vascular events and renal events. The secondary endpoints were effects on left ventricular hypertrophy, cardiac sympathetic nerve activity and renal function. A total of 1021 patients were enrolled in the present trial. The mean follow-up period was 3.4 years. There were no significant differences in blood pressure (BP) levels between the valsartan group and the amlodipine group throughout the trial. There was no significant difference in the primary endpoint between the two groups (hazard ratio: 1.0, P=0.843). No difference in any event category of the primary endpoint was noted for either group. However, we observed a significant reduction of left ventricular mass index, as determined by echocardiography, in the valsartan group compared with the amlodipine group. We also observed a significant decrease in cardiac sympathetic nerve activity in the valsartan group but not in the amlodipine group. Moreover, there was a significant reduction in the urinary albumin to creatinine ratio in the valsartan group but not in the amlodipine group. Therefore, although BP levels were well controlled and remained equal in the two groups, valsartan had more protective effects on the heart and kidney than amlodipine in Japanese hypertensive patients.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf Ndb4351636fac4cfd94f2697c347fbacd
31 Ndf73c2d1746c4e3cbcccf527999fdcab
32 sg:journal.1313717
33 schema:keywords Amlodipine Randomized Trial
34 BP levels
35 II receptor blocker valsartan
36 Japanese essential hypertensive patients
37 Japanese hypertensive patients
38 Secondary endpoints
39 Valsartan Amlodipine Randomized Trial
40 activity
41 albumin
42 amlodipine
43 amlodipine group
44 angiotensin II receptor blocker valsartan
45 beneficial effects
46 blinded end point trial
47 blocker amlodipine
48 blocker valsartan
49 blood pressure levels
50 calcium channel blocker amlodipine
51 cardiac events
52 cardiac sympathetic nerve activity
53 cardiorenal protection
54 cardiovascular events
55 categories
56 cause death
57 cerebrovascular death
58 channel blocker amlodipine
59 composites
60 creatinine ratio
61 death
62 decrease
63 differences
64 echocardiography
65 effect
66 effect of valsartan
67 end point
68 endpoint
69 essential hypertensive patients
70 event categories
71 events
72 follow
73 function
74 group
75 heart
76 hypertensive patients
77 hypertrophy
78 index
79 kidney
80 left ventricular hypertrophy
81 levels
82 mass index
83 mean follow
84 multicenter
85 nerve activity
86 patients
87 period
88 point
89 point trial
90 present trial
91 pressure levels
92 primary end point
93 primary endpoint
94 protection
95 protective effect
96 randomized trials
97 ratio
98 receptor blocker valsartan
99 reduction
100 renal events
101 renal function
102 significant decrease
103 significant differences
104 significant reduction
105 sudden death
106 sympathetic nerve activity
107 total
108 trials
109 urinary albumin
110 valsartan
111 valsartan group
112 vascular events
113 ventricular hypertrophy
114 ventricular mass index
115 years
116 schema:name Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial
117 schema:pagination 62-69
118 schema:productId N899766ad10444dd8aeb1b670a009d975
119 Nab3db74b8f3b43c18717ac41468512c1
120 Nddde9094dd534f81a8d68a630f6d1481
121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046315851
122 https://doi.org/10.1038/hr.2010.186
123 schema:sdDatePublished 2022-01-01T18:21
124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
125 schema:sdPublisher Nd61e8d717c6d4b899a15b3a9237fae00
126 schema:url https://doi.org/10.1038/hr.2010.186
127 sgo:license sg:explorer/license/
128 sgo:sdDataset articles
129 rdf:type schema:ScholarlyArticle
130 N0c228d2d2b274781b02d3230fbf7ec71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 N1beabae6917c4a259535dbb8e270c6e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Female
135 rdf:type schema:DefinedTerm
136 N26faf52020314f0db836928cba967cbc rdf:first Na296e1a083824b0b9d8c4a0263afa6c6
137 rdf:rest rdf:nil
138 N4042ea06078c45c1bf788f2fb9228284 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 N4282af8df3e84e679f60dc1d4a20114c rdf:first sg:person.01135073733.57
142 rdf:rest N576167af1aab487d9891bba089abbf9a
143 N49e4fdd0fbc749328b15e450c07fbbe3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Treatment Outcome
145 rdf:type schema:DefinedTerm
146 N576167af1aab487d9891bba089abbf9a rdf:first sg:person.01251322333.16
147 rdf:rest Nba5e8f682d5c4099be28c0c2a4033372
148 N6f4ca4e1feec44288810e37892755ed1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antihypertensive Agents
150 rdf:type schema:DefinedTerm
151 N712358ee8c774639bab87ae7deb88147 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Kidney Diseases
153 rdf:type schema:DefinedTerm
154 N725bfdfb84fb41f3a9d94bacac7f93c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Blood Pressure
156 rdf:type schema:DefinedTerm
157 N7e1cbd3a6ec144189670ceeaeb861bea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Amlodipine
159 rdf:type schema:DefinedTerm
160 N87dad4df9521423285ffa3d7abb35f8e rdf:first sg:person.01012024207.33
161 rdf:rest N26faf52020314f0db836928cba967cbc
162 N899766ad10444dd8aeb1b670a009d975 schema:name pubmed_id
163 schema:value 20927112
164 rdf:type schema:PropertyValue
165 N96338d5f59724a25830d561ba5b18fdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Valsartan
167 rdf:type schema:DefinedTerm
168 Na4b379af323b42d597be42293b02a3a2 rdf:first sg:person.01203207133.99
169 rdf:rest Nc9478c5d1ab1455289af1391fd32e824
170 Nab3db74b8f3b43c18717ac41468512c1 schema:name dimensions_id
171 schema:value pub.1046315851
172 rdf:type schema:PropertyValue
173 Nab75eeb3faf740c39e138c958cb606dc rdf:first sg:person.01066760533.40
174 rdf:rest N4282af8df3e84e679f60dc1d4a20114c
175 Nacc522431d54415b8a42aa88d2ed0e15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Asian Continental Ancestry Group
177 rdf:type schema:DefinedTerm
178 Nb14476c352e3442cb297a3b21c81c717 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Cardiovascular Diseases
180 rdf:type schema:DefinedTerm
181 Nba5e8f682d5c4099be28c0c2a4033372 rdf:first sg:person.0752532133.65
182 rdf:rest N87dad4df9521423285ffa3d7abb35f8e
183 Nc4477d58494149e2972b83ef2d82be44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Tetrazoles
185 rdf:type schema:DefinedTerm
186 Nc6ce66f9ce674fc594ff6bedb6d631ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Aged
188 rdf:type schema:DefinedTerm
189 Nc9478c5d1ab1455289af1391fd32e824 rdf:first sg:person.0624235222.83
190 rdf:rest Nab75eeb3faf740c39e138c958cb606dc
191 Nd61e8d717c6d4b899a15b3a9237fae00 schema:name Springer Nature - SN SciGraph project
192 rdf:type schema:Organization
193 Nd8aa6a9fd3794709b99ebbd6c3a47ec5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Male
195 rdf:type schema:DefinedTerm
196 Ndb4351636fac4cfd94f2697c347fbacd schema:volumeNumber 34
197 rdf:type schema:PublicationVolume
198 Nddde9094dd534f81a8d68a630f6d1481 schema:name doi
199 schema:value 10.1038/hr.2010.186
200 rdf:type schema:PropertyValue
201 Ndf73c2d1746c4e3cbcccf527999fdcab schema:issueNumber 1
202 rdf:type schema:PublicationIssue
203 Nf6825a6a79584f8a9b607aed6f84b4ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Valine
205 rdf:type schema:DefinedTerm
206 Nf8946af8dc4145f5a68086b4b2a1f6c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Hypertension
208 rdf:type schema:DefinedTerm
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
213 schema:name Cardiorespiratory Medicine and Haematology
214 rdf:type schema:DefinedTerm
215 sg:journal.1313717 schema:issn 0916-9636
216 1348-4214
217 schema:name Hypertension Research
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01012024207.33 schema:affiliation grid-institutes:grid.136304.3
221 schema:familyName Komuro
222 schema:givenName Issei
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33
224 rdf:type schema:Person
225 sg:person.01066760533.40 schema:affiliation grid-institutes:grid.136304.3
226 schema:familyName Shindo
227 schema:givenName Satoshi
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066760533.40
229 rdf:type schema:Person
230 sg:person.01135073733.57 schema:affiliation grid-institutes:grid.136304.3
231 schema:familyName Fujita
232 schema:givenName Miwa
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135073733.57
234 rdf:type schema:Person
235 sg:person.01203207133.99 schema:affiliation grid-institutes:grid.136304.3
236 schema:familyName Narumi
237 schema:givenName Hiroya
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99
239 rdf:type schema:Person
240 sg:person.01251322333.16 schema:affiliation grid-institutes:grid.136304.3
241 schema:familyName Mizuma
242 schema:givenName Hiroshi
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251322333.16
244 rdf:type schema:Person
245 sg:person.0624235222.83 schema:affiliation grid-institutes:grid.136304.3
246 schema:familyName Takano
247 schema:givenName Hiroyuki
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624235222.83
249 rdf:type schema:Person
250 sg:person.0752532133.65 schema:affiliation grid-institutes:grid.136304.3
251 schema:familyName Kuwabara
252 schema:givenName Yoichi
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752532133.65
254 rdf:type schema:Person
255 sg:pub.10.1007/s00125-002-0946-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1013509783
256 https://doi.org/10.1007/s00125-002-0946-y
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s001250051259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035073261
259 https://doi.org/10.1007/s001250051259
260 rdf:type schema:CreativeWork
261 sg:pub.10.1291/hypres.31.1171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012898116
262 https://doi.org/10.1291/hypres.31.1171
263 rdf:type schema:CreativeWork
264 sg:pub.10.1291/hypres.31.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010763509
265 https://doi.org/10.1291/hypres.31.21
266 rdf:type schema:CreativeWork
267 grid-institutes:grid.136304.3 schema:alternateName Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
268 schema:name Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
269 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...